Asset
RMC-5552
Revolution Medicines Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04774952 | phase1 | completed | 2021-04-07 | 2024-05-06 | Revolution Medicines, Inc. | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.